Xcovery Appoints Expert in Targeted Cancer Therapeutics
Published: Jun 19, 2012
WEST PALM BEACH, Fla. & BOSTON--(BUSINESS WIRE)--Xcovery, a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer, today announced that Dr. Samuel Broder has been appointed Senior Scientific and Clinical Strategist. Dr. Broder is a recognized expert in targeted cancer therapeutics and will provide guidance as the company develops its pipeline of small molecule kinase inhibitors to target advanced tumors. The Company made the announcement today at the 2012 BIO International Convention Business Forum and is meeting with biopharmaceutical companies for one-on-one meetings.